Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activation syndrome. Highly effective showing ability to lower steroid use #ACR19 #ACRBest https://t.co/OXTwpkyhlq